Figure 2.

Schematic simplified representation of the molecular binding of the monoclonal antibody tezepelumab to the human TSLP with subsequent blocking of its interaction with the heterodimeric TSLP receptor, thus impeding the formation of the TSLPR: TSLP: IL-7Rα ternary complex on effector cells. The CDRs of the VH of tezepelumab target TSLP at the C-terminal region of helix αD and AB loop region (marked by red star), while the VL does not interact with TSLP (adapted after [15]). TSLP represented here in green is the long-form TSLP (the common part with the short-form TSLP is highlighted in light green).